Myriad Genetics (MYGN) Projected to Post Earnings on Tuesday

Key Points

• Myriad Genetics (MYGN) is set to release its Q2 2025 earnings on August 5th, with analysts expecting an earnings per share of ($0.02) and revenue of $202.30 million.
• In its last earnings report, Myriad Genetics reported ($0.03) EPS, surpassing expectations, but experienced a significant revenue decline of 33.6% year-over-year.
• The stock has seen recent analysis downgrades, with price targets lowered by firms such as UBS and Goldman Sachs, reflecting a cautious outlook among analysts.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) will likely be announcing its Q2 2025 earnings results after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $202.30 million for the quarter. Myriad Genetics has set its FY 2025 guidance at -0.020-0.020 EPS.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.02. The company had revenue of $195.90 million for the quarter, compared to analyst estimates of $200.37 million. Myriad Genetics had a negative net margin of 12.20% and a negative return on equity of 4.95%. The business's revenue for the quarter was down 33.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.01) earnings per share. On average, analysts expect Myriad Genetics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Myriad Genetics Trading Up 1.7%

NASDAQ:MYGN traded up $0.07 on Friday, reaching $3.91. 969,322 shares of the company's stock were exchanged, compared to its average volume of 1,634,318. The company has a quick ratio of 1.71, a current ratio of 1.90 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $359.96 million, a price-to-earnings ratio of -3.49 and a beta of 1.91. The business has a fifty day moving average of $4.89 and a 200-day moving average of $8.01. Myriad Genetics has a 52-week low of $3.76 and a 52-week high of $29.30.

Institutional Investors Weigh In On Myriad Genetics

Large investors have recently modified their holdings of the company. Baird Financial Group Inc. acquired a new stake in shares of Myriad Genetics in the first quarter valued at approximately $105,000. Royal Bank of Canada raised its stake in shares of Myriad Genetics by 82.4% during the first quarter. Royal Bank of Canada now owns 33,326 shares of the company's stock worth $296,000 after purchasing an additional 15,057 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Myriad Genetics by 1,076.9% during the first quarter. Jane Street Group LLC now owns 213,826 shares of the company's stock worth $1,897,000 after purchasing an additional 195,658 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Myriad Genetics by 4.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,256 shares of the company's stock worth $2,654,000 after purchasing an additional 14,027 shares during the last quarter. Finally, AQR Capital Management LLC raised its stake in shares of Myriad Genetics by 278.9% during the first quarter. AQR Capital Management LLC now owns 433,392 shares of the company's stock worth $3,844,000 after purchasing an additional 319,007 shares during the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. The Goldman Sachs Group cut their price target on shares of Myriad Genetics from $14.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. UBS Group cut their price target on shares of Myriad Genetics from $16.00 to $7.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Craig Hallum set a $18.00 price target on shares of Myriad Genetics and gave the stock a "buy" rating in a research note on Wednesday, May 7th. Piper Sandler cut their price target on shares of Myriad Genetics from $12.50 to $9.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th. Finally, Scotiabank lowered shares of Myriad Genetics from a "sector outperform" rating to a "sector perform" rating and cut their price target for the stock from $20.00 to $6.00 in a research note on Wednesday, May 21st. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, Myriad Genetics currently has an average rating of "Hold" and an average price target of $14.38.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.